This case does not represent a flaw in the model, since followup EGD was indeed performed as per the model's recommendation, and his risk level at 1.8 years before progression was upgraded to HR.
Cases missing followup data (n = 52), model covariates (n = 189), declining treatment (n = 4), or having multiple primary breast cancers (n = 6), and cases stage 0 (n = 15) and stage IV (n = 27) were excluded.
The investigators found that THA dominated MoM HRA throughout the 20-year followup period of the Markov model, due to the higher cost of MoM HRA and also the higher revision rate resulting in lower quality adjusted life-years.
In our study, albumin presented lower values in patients that died during followup; however, the survival regression models did not show albumin as an independent risk factor.
We developed a mathematical model to optimize outpatient followup regimens for radical cystectomy.
Therefore, if the observed albumin at the end of the trial's followup was lower than that predicted by the model, given the final bilirubin level and the length of followup, this would be consistent with UDCA having no effect on prognosis.
The bilirubin and albumin relationship was closely predicted by our model in the trial with the longest followup [ 16], although bilirubin values were lower.
In our previous report, stent thrombosis did not occur within 6-month followup for the AESs in a porcine coronary artery model [ 37].
When diffuse OA was excluded from the model, the independent predictors of new‐onset WP at followup were age, baseline pain status score, anxiety, poorer physical HRQOL, presence of cognitive complaint, and nonrestorative sleep on most nights.
The extent of lost to followup or missing data was unclear in the analysis for nine models (BTS 1, 2, 3, CURB, IDSA/ATS 2007, mATS, SOAR, A-DROP, and PARB) [ 6, 15, 22– 26, 29, 29].
